These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36102236)

  • 21. Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort.
    Frantzi N; Nguyen XP; Herr C; Alter P; Söhler S; Soriano D; Watz H; Waschki B; Trinkmann F; Eichenlaub M; Trudzinski FC; Michels-Zetsche JD; Omlor A; Seiler F; Moneke I; Biertz F; Rohde G; Stolz D; Welte T; Kauczor HU; Kahnert K; Jörres RA; Vogelmeier CF; Bals R; Fähndrich S;
    Respir Res; 2024 May; 25(1):207. PubMed ID: 38750572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).
    Vogelmeier CF; Asijee GM; Kupas K; Beeh KM
    Adv Ther; 2015 Jun; 32(6):537-47. PubMed ID: 26100349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study.
    Rhodes K; Jenkins M; de Nigris E; Aurivillius M; Ouwens M
    BMC Med Res Methodol; 2022 May; 22(1):150. PubMed ID: 35614467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment.
    Yang SN; Ko HK; Hsiao YH; Su KC; Chang YL; Huang HY; Perng DW; Chung MI
    J Chin Med Assoc; 2019 Jun; 82(6):488-494. PubMed ID: 31180947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
    Panettieri RA; Camargo CA; Cheema T; El Bayadi SG; Fiel S; Vila TM; Jain RG; Midwinter D; Thomashow B; Ludwig-Sengpiel A; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2043-2052. PubMed ID: 36072608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
    Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
    Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
    Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC; Lau H; La HO; Choi IS; Geba GP
    Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline.
    Ferguson GT; Shaikh A; Tetzlaff K; Mueller A; Magnussen H; Watz H
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2879-2888. PubMed ID: 33204084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
    Tkacz J; Evans KA; Touchette DR; Portillo E; Strange C; Staresinic A; Feigler N; Patel S; Pollack M
    Int J Chron Obstruct Pulmon Dis; 2022; 17():329-342. PubMed ID: 35177901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of severe cardiovascular events following COPD exacerbations: results from the EXACOS-CV study in Spain.
    Santos S; Manito N; Sánchez-Covisa J; Hernández I; Corregidor C; Escudero L; Rhodes K; Nordon C
    Rev Esp Cardiol (Engl Ed); 2024 Jun; ():. PubMed ID: 38936468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers.
    Chapman KR; Wise RA; Scirica BM; Bhatt DL; Daoud SZ; Lythgoe D; Gil EG
    Respir Res; 2021 Oct; 22(1):272. PubMed ID: 34686204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.
    Wang MT; Liou JT; Lin CW; Tsai CL; Wang YH; Hsu YJ; Lai JH
    JAMA Intern Med; 2018 Feb; 178(2):229-238. PubMed ID: 29297057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exacerbation Risk and Mortality in Global Initiative for Chronic Obstructive Lung Disease Group A and B Patients with and without Exacerbation History.
    Vanfleteren LEGW; Lindberg A; Zhou C; Nyberg F; Stridsman C
    Am J Respir Crit Care Med; 2023 Jul; 208(2):163-175. PubMed ID: 37040482
    [No Abstract]   [Full Text] [Related]  

  • 36. Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients.
    Løkke A; Hilberg O; Lange P; Ibsen R; Stratelis G; de Fine Licht S; Lykkegaard J
    Int J Chron Obstruct Pulmon Dis; 2022; 17():569-578. PubMed ID: 35321533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
    Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
    Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial.
    Thomashow B; Stiegler M; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Lange P; Martinez FJ; Midwinter D; Singh D; Tabberer M; Wise RA; Lipson DA; Jones P
    Chronic Obstr Pulm Dis; 2022 Jan; 9(1):68-79. PubMed ID: 34972260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.
    Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Vekeman F; Gauthier-Loiselle M; Duh MS; Merrigan JF; Schatz M
    Ann Am Thorac Soc; 2016 Jul; 13(7):1067-75. PubMed ID: 27070274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.